Bradsher Neal C 4

4 · Lineage Cell Therapeutics, Inc. · Filed Jul 2, 2026

AI-generated summary of this filing

Updated Jul 2, 2026

Lineage (LCTX) Director Neal C. Bradsher Receives Option Award

What Happened

Neal C. Bradsher, a director and reported 10% owner of Lineage Cell Therapeutics, Inc. (LCTX), received a grant of 125,000 derivative awards (described as options) on July 1, 2026. The Form 4 reports an acquisition price of $0.00 for the award and lists the transaction as a derivative grant (125,000 shares, $0 total).

Key Details

Transaction date and price: July 1, 2026; 125,000 options/awards reported at $0.00.
Transaction type: Award/Grant (derivative), filed on Form 4 with period of report 2026-07-01 and filing date 2026-07-02 (timely filing).
Shares owned after transaction: Not specified in the provided excerpt of the filing.
Footnotes of note:
- F1: Vesting: options vest and become exercisable on the earlier of (a) July 1, 2027 or (b) the Issuer’s next annual meeting after the grant date, subject to continuous service.
- F2: Grant was made as director compensation under the Issuer’s 2021 Equity Incentive Plan.
- F3: The filing also states these options are currently exercisable (as reported).
No late filing flag indicated in the provided data.

Context

This was a compensation award (not an open-market purchase or sale). As a derivative grant, it does not represent an immediate purchase of shares; the filing indicates these are options/awards that may convert into shares under the plan’s terms. Because Bradsher is both a director and a 10% owner, the grant is part of insider compensation rather than a standalone market trade.

Form 4

Period: 2026-07-01

Director10% Owner

Transactions

Award
OPTION TO PURCHASE COMMON SHARES
[F2][F1]
2026-07-01+125,000→ 125,000 total
Exercise: $1.30Exp: 2036-07-01→ COMMON SHARES (125,000 underlying)

Holdings

OPTION TO PURCHASE COMMON SHARES
[F3]
Exercise: $0.90Exp: 2035-07-01→ COMMON SHARES (75,000 underlying)
75,000
OPTION TO PURCHASE COMMON SHARES
[F3]
Exercise: $0.95Exp: 2034-07-01→ COMMON SHARES (75,000 underlying)
75,000
OPTION TO PURCHASE COMMON SHARES
[F3]
Exercise: $1.41Exp: 2033-07-01→ COMMON SHARES (50,000 underlying)
50,000
OPTION TO PURCHASE COMMON SHARES
[F3]
Exercise: $1.57Exp: 2032-07-01→ COMMON SHARES (50,000 underlying)
50,000
OPTION TO PURCHASE COMMON SHARES
[F3]
Exercise: $2.86Exp: 2031-07-01→ COMMON SHARES (50,000 underlying)
50,000
OPTION TO PURCHASE COMMON SHARES
[F3]
Exercise: $0.83Exp: 2030-07-01→ COMMON SHARES (40,000 underlying)
40,000
OPTION TO PURCHASE COMMON SHARES
[F3]
Exercise: $1.03Exp: 2029-06-30→ COMMON SHARES (40,000 underlying)
40,000

Footnotes (3)

[F1]These options will vest and become exercisable on the earlier of: (a) July 1, 2027 and (b) the date of Lineage Cell Therapeutics, Inc.'s (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.
[F2]These options were granted to the Reporting Person by the Issuer on July 1, 2026 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
[F3]These options are currently exercisable.

Signature

Neal C. Bradsher, /s/ Neal C. Bradsher|2026-07-02

1 file